- Home
- DXLG vs BRNS Comparison
DXLG vs BRNS Comparison
Compare DXLG & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- BRNS
- Stock Information
- Founded
- DXLG 1976
- BRNS 2016
- Country
- DXLG United States
- BRNS United Kingdom
- Employees
- DXLG N/A
- BRNS N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- DXLG Consumer Discretionary
- BRNS Health Care
- Exchange
- DXLG Nasdaq
- BRNS Nasdaq
- Market Cap
- DXLG 55.4M
- BRNS 58.0M
- IPO Year
- DXLG 1987
- BRNS 2021
- Fundamental
- Price
- DXLG $1.17
- BRNS $1.61
- Analyst Decision
- DXLG Strong Buy
- BRNS Strong Buy
- Analyst Count
- DXLG 1
- BRNS 1
- Target Price
- DXLG $2.50
- BRNS $3.00
- AVG Volume (30 Days)
- DXLG 73.2K
- BRNS 248.2K
- Earning Date
- DXLG 11-21-2025
- BRNS 11-05-2025
- Dividend Yield
- DXLG N/A
- BRNS N/A
- EPS Growth
- DXLG N/A
- BRNS N/A
- EPS
- DXLG N/A
- BRNS N/A
- Revenue
- DXLG $447,744,000.00
- BRNS $14,969,000.00
- Revenue This Year
- DXLG N/A
- BRNS N/A
- Revenue Next Year
- DXLG $4.93
- BRNS N/A
- P/E Ratio
- DXLG N/A
- BRNS N/A
- Revenue Growth
- DXLG N/A
- BRNS 1766.46
- 52 Week Low
- DXLG $0.90
- BRNS $0.64
- 52 Week High
- DXLG $3.10
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- DXLG 36.16
- BRNS 65.26
- Support Level
- DXLG $1.29
- BRNS $1.36
- Resistance Level
- DXLG $1.31
- BRNS $1.67
- Average True Range (ATR)
- DXLG 0.07
- BRNS 0.17
- MACD
- DXLG -0.02
- BRNS 0.05
- Stochastic Oscillator
- DXLG 3.34
- BRNS 72.15
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.